GlassScriptPhysician profile
Donald R Atkinson
NPI 1205938446
$8,309.26
in general payments reported to CMS, 2019-2025
23 companies · $578 in 2025
The $578 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,043 · 2020: $1,072 · 2021: $636 · 2022: $1,246 · 2023: $1,995 · 2024: $739 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,173 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.09 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,325.88 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,178.74 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,074.48 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $786.06 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $585.62 | 2019-2023 | Rexulti |
| Abbvie INC. | $558.84 | 2021-2024 | Vraylar |
| Vanda Pharmaceuticals INC. | $543.15 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $411.17 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Allergan, INC. | $369.25 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $338.64 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $283.80 | 2019-2023 | Invega Sustenna, Invega Trinza, Spravato |
| E.R. Squibb & Sons, L.L.C. | $154.05 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $141.34 | 2022-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $129.53 | 2023-2025 | Auvelity |
| Corium, LLC | $114.38 | 2023 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $83.21 | 2022-2023 | Perseris |
| Ironshore Pharmaceuticals INC. | $47.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.79 | 2019-2022 | |
| Eisai INC. | $38.91 | 2020 | |
| Tris Pharma INC | $38.68 | 2020 | |
| Avanir Pharmaceuticals, INC. | $28.47 | 2019 | |
| Gilead Sciences, INC. | $26.38 | 2023 | |
| Adlon Therapeutics L.P. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.